Dmsa Izotóp Intézet

Dimercaptosuccinic Acid (DMSA), the active ingredient in Dmsa Izotóp Intézet, is a chelating agent presented as a 1.5 mg/3.0 mg por oldatos injekcióhoz for intravenous use. It is used to treat heavy metal poisoning, such as lead, mercury, and arsenic poisoning, in patients who require chelation therapy. GNH USA supplies Dmsa Izotóp Intézet as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies, and clinics worldwide.

Dmsa Izotóp Intézet is a critical medication for managing acute and chronic heavy metal toxicity. Its formulation ensures effective delivery and rapid action, making it a reliable choice for healthcare professionals dealing with poisoning cases.

Dmsa Izotóp Intézet is primarily used in the treatment of heavy metal poisoning. It helps to bind and remove toxic metals from the body, reducing their harmful effects.

- Lead poisoning: Reduces lead levels in the blood and tissues, mitigating neurological and systemic damage. - Mercury poisoning: Facilitates the excretion of mercury, decreasing its toxic impact on the kidneys and nervous system. - Arsenic poisoning: Binds arsenic to form stable complexes that are excreted, thereby reducing arsenic-induced toxicity.

Dmsa Izotóp Intézet may cause side effects, ranging from common to serious. Patients should be monitored closely during treatment.

Common Side Effects: - Nausea and vomiting: Mild gastrointestinal discomfort may occur. - Diarrhea: Loose stools or frequent bowel movements may be experienced. - Headache: Some patients may report mild to moderate headaches. - Rash: Skin irritation or mild allergic reactions may occur.

Serious or Rare Side Effects: - Allergic reactions: Severe allergic reactions, including anaphylaxis, are rare but possible. - Liver toxicity: Elevated liver enzymes or liver dysfunction may occur in some cases. - Kidney dysfunction: Impaired kidney function may be observed, particularly in patients with pre-existing renal issues.

Dmsa Izotóp Intézet should be used with caution and under medical supervision. Certain precautions and warnings should be observed to ensure safe and effective treatment.

- Pregnancy: Use during pregnancy should be carefully evaluated by a healthcare provider, as the safety of DMSA in pregnant women is not well established. - Breastfeeding: The use of DMSA during breastfeeding should be discussed with a healthcare provider to assess potential risks to the infant. - Renal impairment: Patients with kidney disease should be monitored closely for signs of worsening renal function. - Hepatic impairment: Liver function tests should be performed regularly in patients with liver disease. - Allergies: Patients with known allergies to DMSA or similar chelating agents should avoid this medication. - Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Dmsa Izotóp Intézet may interact with other medications, potentially altering their effectiveness or increasing the risk of side effects. Healthcare providers should be informed of all medications being taken.

Major Interactions (Avoid): - Other chelating agents: Concurrent use with other chelating agents may increase the risk of toxicity or reduce the effectiveness of DMSA. - Penicillamine: May enhance the risk of adverse effects when used together with DMSA.

Moderate Interactions (Monitor Closely): - Antacids: May reduce the absorption of DMSA, potentially decreasing its effectiveness. - Iron supplements: May interfere with the chelation process, requiring close monitoring. - Zinc supplements: May affect the binding and excretion of heavy metals, necessitating careful observation.